2018 News Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
02/14/18Merus Announces $55.8 Million Private Placement Offering of Common Stock
UTRECHT, The Netherlands, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that it has agreed to sell 3.1 million shares of its common shares to Biotechnology Value Fund, L.P. and certain of its affiliates (BVF), Aquilo Capital Management (Aquilo), Sofinnova Venture Partners L.P., and LSP Life Sciences Fund NV in a private placement. Merus anticipates aggrega... 
Printer Friendly Version
02/05/18Merus Announces Participation in Four Investor Conferences in February 2018
UTRECHT, The Netherlands, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the Company’s management will participate at four upcoming investor conferences in February, including: BioCapital Europe 2018 Mark Throsby, Ph.D., Executive Vice President and Chief Scientific Officer, will present on February 6, 2018 at 3:20 p.m. CET in Amsterdam, T... 
Printer Friendly Version
01/26/18Merus Announces First Patient Dosed in a Phase 2 Clinical Trial of MCLA-128 in Two Metastatic Breast Cancer Patient Populations
Combination trial to evaluate MCLA-128 in HER2-positive and hormone receptor-positive/HER2-low metastatic breast cancer patients UTRECHT, the Netherlands, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the first patient has been dosed in a Phase 2, open-label, multi-center international clinical trial to evaluate MCLA-128 in two metastatic breast canc... 
Printer Friendly Version
01/08/18Merus and Simcere Announce Strategic Collaboration on Multiple Bispecific Antibodies
UTRECHT, Netherlands and NANJING, China, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Merus (Nasdaq:MRUS) and Simcere Pharmaceutical Group today announced that Merus has agreed to grant Simcere an exclusive license to develop and commercialize in China three bispecific antibodies utilizing Merus’ proprietary Biclonics® technology platform in the area of immuno-oncology. Merus will retain all rights outside of China.  Under the terms of the agreement, Merus has agreed to lead research and discovery act... 
Printer Friendly Version
01/04/18Merus Provides Clinical Updates for MCLA-117 and MCLA-158 Programs
- IND submitted to U.S. FDA for MCLA-117 in AML - - First CTA approval for MCLA-158 received in European country -  UTRECHT, The Netherlands, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MCLA-117 for the potential treatment of acute myelo... 
Printer Friendly Version
01/02/18Merus to Present at the 36th Annual J.P. Morgan Healthcare Conference
UTRECHT, The Netherlands, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview at the 36th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018, at 9:30 a.m. PT.  A live webcast of the presentation will be available on the Investors page of the Company's website, http://www... 
Printer Friendly Version

RSS FeedsFinancial Tear SheetE-mail PagePrint PageE-mail Alerts